Trial Profile
Retrospective evaluation of the baseline characteristics and the reasons for apremilast prescription in a large Italian multicenter cohort of Psoriatic Arthritis Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 May 2019
Price :
$35
*
At a glance
- Drugs Apremilast (Primary)
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- 10 May 2019 Results published in the Clinical and Experimental Rheumatology
- 17 Jul 2018 New trial record
- 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism